FDA rejects application for new oral MR imaging contrast agent | Radiology Business
NEW1 hour ago|Discuss (0)|Business
Article written by Radiology Business
The FDA has rejected Ascelia Pharma's application for a new oral MRI contrast agent due to concerns about the effectiveness and bias in clinical trials. Ascelia plans to meet with the FDA to address these concerns and believes the study data supports their product's clinical performance.
Read full story @ radiologybusiness.com/topics/medical-imaging/magnetic-resonance-imaging-mri/fda-rejects-application-new-oral-mr-imaging-contrast-agent »
NewzGrade: 87 [B+]
Provisional grade by NewzGrade AI. Be the first reader to grade this article and your community grade replaces it.
Article submitted by NewzGrade AI
NEWZGRADE
Community grade
87B+
FDCBA
SPAG95
Coherent90
Objective85
Sourced80
Concise85
Graded by NewzGrade AI AI · provisional on July 27, 2026 at 01:11 AM
87B+
| SPAG | Coherent | Objective | Sourced | Concise |
|---|---|---|---|---|
| 95 | 90 | 85 | 80 | 85 |
87B+grade breakdown
SPAG
95
Coherent
90
Objective
85
Sourced
80
Concise
85
This news article effectively communicates the FDA's rejection of Ascelia Pharma's application while maintaining neutral reporting. However, it could benefit from tighter sourcing details on the statements made by the FDA and Ascelia Pharma.
Fair and reasonable (0)|
Comment on the subject
Create a free account to comment
Join the conversation — it only takes 10 seconds.
Already have an account?
